Evidence map›Paper›PMID 31948066›Full record

ArticleInternational journal of molecular sciences2020

Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.

Boichuk Sergei, Dunaev Pavel, Galembikova Aigul, Bikinieva Firyuza, Nurgatina Ilmira, Mustafin Ilshat, Aukhadieva Aida, Kurtasanov Refat, Andriutsa Natalia, Shagimardanova Elena and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Angiogenesis in gastrointestinal stromal tumors: From bench to bedside.World journal of gastrointestinal oncology · 2022
    Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Boichuk SergeiDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.
Dunaev PavelDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.
Galembikova AigulDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-0293-2974
Bikinieva FiryuzaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.
Nurgatina IlmiraDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.
Mustafin IlshatDepartment of Biochemistry, Kazan State Medical University, Kazan 420012, Russia.
Aukhadieva AidaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.
Kurtasanov RefatTatarstan Cancer Center, Kazan 420029, Russia.
Andriutsa NataliaDepartment of Pathophysiology, I.M. Sechenov First Moscow State Medical University, Moscow 119146, Russia.ORCID 0000-0001-5425-7707
Shagimardanova ElenaInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan 420008, Russia.
Gorbunova VeraDepartment of Biology, University of Rochester, Rochester, NY 14627, USA.
Kazan State Medical University · RUKazan Federal University · RUKazan Scientific Center · RUSechenov University · RUUniversity of Rochester · US

Funding

Российский Фонд Фундаментальных Исследований (РФФИ) 17-04-00158A
6 · The paper itself

Abstract

Deregulation of receptor tyrosine kinase (RTK)-signaling is frequently observed in many human malignancies, making activated RTKs the promising therapeutic targets. In particular, activated RTK-signaling has a strong impact on tumor resistance to various DNA damaging agents, e.g., ionizing radiation and chemotherapeutic drugs. We showed recently that fibroblast growth factor receptor (FGFR)-signaling might be hyperactivated in imatinib (IM)-resistant gastrointestinal stromal tumors (GIST) and inhibition of this pathway sensitized tumor cells to the low doses of chemotherapeutic agents, such as topoisomerase II inhibitors. Here, we report that inhibition of FGFR-signaling in GISTs attenuates the repair of DNA double-strand breaks (DSBs), which was evidenced by the delay in γ-H2AX decline after doxorubicin (Dox)-induced DNA damage. A single-cell gel electrophoresis (Comet assay) data showed an increase of tail moment in Dox-treated GIST cells cultured in presence of BGJ398, a selective FGFR1-4 inhibitor, thereby revealing the attenuated DNA repair. By utilizing GFP-based reporter constructs to assess the efficiency of DSBs repair via homologous recombination (HR) and non-homologous end-joining (NHEJ), we found for the first time that FGFR inhibition in GISTs attenuated the homology-mediated DNA repair. Of note, FGFR inhibition/depletion did not reduce the number of BrdU and phospho-RPA foci in Dox-treated cells, suggesting that inhibition of FGFR-signaling has no impact on the processing of DSBs. In contrast, the number of Dox-induced Rad51 foci were decreased when FGFR2-mediated signaling was interrupted/inhibited by siRNA FGFR2 or BGJ398. Moreover, Rad51 and -H2AX foci were mislocalized in FGFR-inhibited GIST and the amount of Rad51 was substantially decreased in -H2AX-immunoprecipitated complexes, thereby illustrating the defect of Rad51 recombinase loading to the Dox-induced DSBs. Finally, as a result of the impaired homology-mediated DNA repair, the increased numbers of hypodiploid (i.e., apoptotic) cells were observed in FGFR2-inhibited GISTs after Dox treatment. Collectively, our data illustrates for the first time that inhibition of FGF-signaling in IM-resistant GIST interferes with the efficiency of DDR signaling and attenuates the homology-mediated DNA repair, thus providing the molecular mechanism of GIST's sensitization to DNA damaging agents, e.g., DNA-topoisomerase II inhibitors.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorDNA Breaks, Double-StrandedDoxorubicinGastrointestinal NeoplasmsGastrointestinal Stromal TumorsGene Knockdown TechniquesGene SilencingHistonesHumansImatinib MesylatePhenylurea CompoundsProto-Oncogene Proteins c-aktPyrimidinesRad51 RecombinaseAntineoplastic AgentsDoxorubicinFGFR2 protein, humanH2AX protein, humanHistonesImatinib MesylateinfigratinibPhenylurea CompoundsProto-Oncogene Proteins c-aktPyrimidinesRAD51 protein, humanRad51 RecombinaseReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 2RNA, Small InterferingTopoisomerase II InhibitorsDNA-topoisomerase II inhibitorsFGFR-signalinggastrointestinal stromal tumor cells (GIST)homology-mediated DNA repairimatinib mesylate (IM)Rad51 recombinaseresistance

Identifiers

PMID31948066
PMCPMC6982350
OpenAlexW2997819750

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.